ACET · Adicet Bio, Inc.

Adicet Bio reported its first quarter 2026 financial results, highlighting a reduced net loss of $20.2 million compared to $28.2 million in the same period last year. The improvement was driven by lower operating expenses: R&D expenses decreased to $17.5 million from $22.8 million, primarily due to a $3.6 million reduction in payroll and personnel expenses from lower headcount, a $1.4 million decrease in lab supplies, and a $0.5 million decrease in CRO expenses, partially offset by a $0.4 million increase in professional fees. G&A expenses fell to $4.1 million from $7.1 million, mainly due to lower stock-based compensation and headcount. The company ended the quarter with $137.6 million in cash, equivalents, and short-term investments, which management expects to fund operations into the second half of 2027. On the operational front, Adicet is approaching a key inflection point with its Phase 1 prula-cel program in autoimmune diseases. The company plans to report clinical data in mid-2026 from at least 20 lupus nephritis and SLE patients with a minimum of six months of follow-up. An FDA interaction is expected in Q2 2026 to inform potential pivotal trial design, with startup activities for a pivotal program anticipated in the second half of 2026. Additionally, Adicet plans to submit a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in Q3 2026, with Phase 1 enrollment expected to begin in Q4 2026 pending clearance. The company continues to advance its pipeline and in vivo CAR-T platform. Management's commentary underscores a focus on near-term data readouts and regulatory milestones.